Performance and outcome of the subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction.

Aims: The subcutaneous cardioverter-defibrillator (S-ICD) may be a valuable option in patients after successful transvenous lead extraction (TLE) without indication for pacemaker therapy and persistent risk of sudden cardiac death. The aim of this study was to evaluate device performance, postoperative outcome, and safety in patients who received a S-ICD after TLE compared to patients who underwent de-novo S-ICD implantation.

Methods: A retrospective analysis of all patients included into our institution's S-ICD database between September 2010 and May 2019 was conducted.

[Guideline-Based Indications on Pacing and ICD-Therapy].

In 2016, there were 77 293 pacemakers and 28 953 ICDs implanted in Germany. This makes pacemaker- and ICD-implantations part of the most frequently performed operations in Germany. This article addresses questions of correct indication and patient selection.

Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial.

Background: Platelet inhibition has been linked to improved endothelial function, a prognostic factor in coronary artery disease. Whether prasugrel, a potent platelet inhibitor, affects endothelial function remains unknown.

Methods: This was a double-blind, randomized, active-controlled, parallel trial.